Legislative Research: NY A11279 | 2017-2018 | General Assembly
Other Sessions
| Session | Title/Description | Last Action |
|---|---|---|
| 2017-2018 General Assembly (Introduced - Dead) | Requires dihydropyrimidine dehydrogenase deficiency testing prior to fluoropyrmidine or other antimetabolite treatment; requires policies and contracts of insurance to include coverage for dihydropyrimidine dehydrogenase deficiency testing; provides ... [A11279 2017 Detail][A11279 2017 Text][A11279 2017 Comments] | 2018-07-25 referred to health |
| 2009-2010 General Assembly (Introduced - Dead) | To extend the eligibility period for the City of New York's Commercial Expansion Program until 2014. [A11279 2009 Detail][A11279 2009 Text][A11279 2009 Comments] | 2010-06-29 substituted by s8173 |
References Online
| Search Phrase | Web | News | Financial | Encylopedia | Biography |
|---|---|---|---|---|---|
| [New York A11279] | Google Web | Google News | |||
| [New York Assembly Health Committee] | Google Web | Google News | FollowTheMoney | ||
| [Assemblymember Patricia Fahy NY] | Google Web | Google News | FollowTheMoney | Ballotpedia | VoteSmart |
Legislative Citation
APA
NY A11279 | 2017-2018 | General Assembly. (2018, July 25). LegiScan. Retrieved May 06, 2024, from https://legiscan.com/NY/bill/A11279/2017
MLA
"NY A11279 | 2017-2018 | General Assembly." LegiScan. LegiScan LLC, 25 Jul. 2018. Web. 06 May. 2024. <https://legiscan.com/NY/bill/A11279/2017>.
Chicago
"NY A11279 | 2017-2018 | General Assembly." July 25, 2018 LegiScan. Accessed May 06, 2024. https://legiscan.com/NY/bill/A11279/2017.
Turabian
LegiScan. NY A11279 | 2017-2018 | General Assembly. 25 July 2018. https://legiscan.com/NY/bill/A11279/2017 (accessed May 06, 2024).
Same As/Similar To
| Bill | Relationship | Date | Title | Last Action |
|---|---|---|---|---|
| S07710 | Same As | 2018-06-19 | Requires dihydropyrimidine dehydrogenase deficiency testing prior to fluoropyrmidine or other antimetabolite treatment; requires policies and contracts of insurance to include coverage for dihydropyrimidine dehydrogenase deficiency testing; provides for dihydropyrimidine dehydrogenase deficiency testing under the medical assistance program. | referred to health |
